Equities

Thor Medical ASA

Thor Medical ASA

Actions
  • Price (EUR)0.0664
  • Today's Change-0.008 / -10.39%
  • Shares traded0.00
  • 1 Year change-8.92%
  • Beta--
Data delayed at least 15 minutes, as of Mar 27 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

  • Revenue in NOK (TTM)--
  • Net income in NOK-5.60m
  • Incorporated2009
  • Employees16.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TRMED:OSL since
announced
Transaction
value
Thor Medical ASDeal completed05 Jun 202305 Jun 2023Deal completed43.20%7.96m
Data delayed at least 15 minutes, as of Mar 27 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.